

Association Between Maternal Use of Folic Acid Supplements and Risk of Autism Spectrum Disorders in Children

Pål Surén, MD, MPH

Christine Roth, MSc

Michaeline Bresnahan, PhD

Margaretha Haugen, PhD

Mady Hornig, MD

Deborah Hirtz, MD

Kari Kveim Lie, MD

W. Ian Lipkin, MD

Per Magnus, MD, PhD

Ted Reichborn-Kjennerud, MD, PhD

Synnve Schjølberg, MSc

George Davey Smith, MD, DSc

Anne-Siri Øyen, PhD

Ezra Susser, MD, DrPH

Camilla Stoltenberg, MD, PhD

SUPPLEMENTATION WITH FOLIC acid around the time of conception reduces the risk of neural tube defects in children.¹⁻⁷ This protective effect has led to mandatory fortification of flour with folic acid in several countries,⁸ and it is generally recommended that women planning to become pregnant take a daily supplement of folic acid starting 1 month before conception.^{8,9}

There also is evidence that maternal folic acid supplementation during pregnancy may be associated with reduced risk of other neurodevelopmental disorders.

For editorial comment see p 611.

Author Video Interview available at www.jama.com.

Importance Prenatal folic acid supplements reduce the risk of neural tube defects in children, but it has not been determined whether they protect against other neurodevelopmental disorders.

Objective To examine the association between maternal use of prenatal folic acid supplements and subsequent risk of autism spectrum disorders (ASDs) (autistic disorder, Asperger syndrome, pervasive developmental disorder—not otherwise specified [PDD-NOS]) in children.

Design, Setting, and Patients The study sample of 85 176 children was derived from the population-based, prospective Norwegian Mother and Child Cohort Study (MoBa). The children were born in 2002-2008; by the end of follow-up on March 31, 2012, the age range was 3.3 through 10.2 years (mean, 6.4 years). The exposure of primary interest was use of folic acid from 4 weeks before to 8 weeks after the start of pregnancy, defined as the first day of the last menstrual period before conception. Relative risks of ASDs were estimated by odds ratios (ORs) with 95% CIs in a logistic regression analysis. Analyses were adjusted for maternal education level, year of birth, and parity.

Main Outcome Measure Specialist-confirmed diagnosis of ASDs.

Results At the end of follow-up, 270 children in the study sample had been diagnosed with ASDs: 114 with autistic disorder, 56 with Asperger syndrome, and 100 with PDD-NOS. In children whose mothers took folic acid, 0.10% (64/61 042) had autistic disorder, compared with 0.21% (50/24 134) in those unexposed to folic acid. The adjusted OR for autistic disorder in children of folic acid users was 0.61 (95% CI, 0.41-0.90). No association was found with Asperger syndrome or PDD-NOS, but power was limited. Similar analyses for prenatal fish oil supplements showed no such association with autistic disorder, even though fish oil use was associated with the same maternal characteristics as folic acid use.

Conclusions and Relevance Use of prenatal folic acid supplements around the time of conception was associated with a lower risk of autistic disorder in the MoBa cohort. Although these findings cannot establish causality, they do support prenatal folic acid supplementation.

JAMA. 2013;309(6):570-577

www.jama.com

Author Affiliations: Norwegian Institute of Public Health, Oslo (Drs Surén, Haugen, Lie, Magnus, Reichborn-Kjennerud, Øyen, and Stoltenberg and Mss Roth and Schjølberg); Centre for Paediatric Epidemiology and Biostatistics, UCL Institute of Child Health, London, United Kingdom (Dr Surén); Mailman School of Public Health, Columbia University, New York, New York (Drs Bresnahan, Hornig, Lipkin, and Susser and Ms Roth); New York State Psychiatric Institute, New York (Drs Bresnahan and Susser); National Institute of Neurological Disorders and Stroke, Bethesda,

Maryland (Dr Hirtz); Institute of Psychiatry, University of Oslo, Oslo (Dr Reichborn-Kjennerud); MRC Centre for Causal Analysis in Translational Epidemiology, University of Bristol, Bristol, United Kingdom (Dr Davey Smith); Nic Waals Institute, Lovisenberg Hospital, Oslo (Dr Øyen); and Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway (Dr Stoltenberg).

Corresponding Author: Pål Surén, MD, MPH, Norwegian Institute of Public Health, PO Box 4404, Nydalen, N-0403 Oslo, Norway (pal.suren@fhi.no).

tal disorders in children. A recent study of 38 954 children in the Norwegian Mother and Child Cohort Study (MoBa) found that maternal intake of folic acid supplements from 4 weeks before to 8 weeks after the start of pregnancy was associated with a lower risk of severe language delay at age 3 years.¹⁰ A case-control study from California of autism spectrum disorders (ASDs) showed that maternal intake of folic acid and prenatal vitamins during the 3 months prior to pregnancy and the first month of pregnancy was associated with a lower risk of ASDs in the offspring, and complementary genetic analyses indicated that the association was modified by gene variants that determine the ability to utilize available folate.^{11,12}

Although ethical considerations preclude placebo-controlled randomized trials that eliminate folic acid, observational studies of mothers who do and do not use supplements may be informative. We used the MoBa cohort to investigate the association between the use of maternal folic acid supplements before and in early pregnancy and the subsequent risk of ASDs (autistic disorder, Asperger syndrome, pervasive developmental disorder—not otherwise specified [PDD-NOS]) in the offspring.

METHODS

Study Population

The MoBa cohort¹³ is nationwide and includes 109 000 children born from 1999 to 2009. Mothers were recruited at ultrasound examinations around week 18 of gestation. Cases of ASD in the cohort are identified by a sub-study of autism, the Autism Birth Cohort (ABC) study.¹⁴ The analyses in this study reflect data collected and processed by March 31, 2012. Participation in MoBa and the ABC study is based on written informed consent from the mother. Both studies were approved by the regional committee of medical research ethics for Southeastern Norway.

Measures of ASD

Cases of ASD are identified through (1) questionnaire screening of mothers at

offspring ages 36 months, 5 years, and 7 years, (2) professional and parental referrals of children suspected of having ASD, and (3) linkages to the Norwegian Patient Registry. Referrals are elicited through annual newsletters to MoBa participants and information on the Norwegian Institute of Public Health website. The Norwegian Patient Registry collects data on diagnoses from all hospitals and outpatient clinics in Norway beginning in the year 2008, thereby capturing data for all children diagnosed with ASD by Norwegian health services.

When a child with ASD or potential ASD is detected through any of the mechanisms described above, he or she is invited to participate in a clinical assessment that includes the research-standard instruments for diagnosis of ASD, the Autism Diagnostic Interview—Revised¹⁵ and the Autism Diagnostic Observation Schedule,¹⁶ which have proven high reliability and validity in making diagnoses of ASD in children. Assessments are conducted without knowledge of previous questionnaire responses. Diagnostic conclusions are best-estimate clinical diagnoses derived from test and interview results and from information collected from parents and teachers. Diagnoses are based on *Diagnostic and Statistical Manual of Mental Disorders* (Fourth Edition) (DSM-IV) criteria, and the case definition includes codes 299.00 (Autistic Disorder), 299.80 (Asperger Syndrome), and 299.80 (Pervasive Developmental Disorder—Not Otherwise Specified).

The registry contains *International Statistical Classification of Diseases, 10th Revision* codes determined by Norwegian specialist health services, and the ASD case definition of the ABC study includes codes F84.0 (Childhood Autism), F84.1 (Atypical Autism), F84.5 (Asperger Syndrome), F84.8 (Other Pervasive Developmental Disorder), and F84.9 (Pervasive Developmental Disorder, Unspecified). In this article, we have used the terms *autistic disorder* for code F84.0 and *PDD-NOS* for codes F84.1, F84.8, and F84.9.

Measures of Folic Acid Use and Dietary Folate Intake


Since 1998, the Norwegian Directorate of Health has recommended that all women attempting to become pregnant should take one 400- μ g folic acid supplement per day from 1 month before conception through the first trimester. Folic acid supplements are available over the counter in Norway. Multivitamin supplements containing folic acid are also available, but at the time participants were recruited to MoBa, all such supplements contained less than 400 μ g of folic acid.

In MoBa, detailed information about the mothers' supplement intake before conception and in early pregnancy was obtained through questionnaire report at week 18 of gestation. No foods were fortified with folic acid at the time when participants were recruited; synthetic supplements thus represented the only source of folate apart from the ordinary diet for the pregnant women. The women were asked to record their intake of vitamins, minerals, and other supplements according to the ingredient lists on the supplement containers, within 4-week intervals from before the start of pregnancy. They were not asked to specify the exact amounts, so if folic acid was only taken as part of a multivitamin supplement, the daily dose would be lower than 400 μ g.

Additional information about supplement use and dietary intake in mid pregnancy was obtained through a food frequency questionnaire completed in week 22. In this questionnaire, women were asked to write the name of supplements they were currently taking (in week 22), and exact amounts of vitamins and minerals were calculated on the basis of this information. The food frequency questionnaire has been described in a previous article¹⁷ and validated through blood samples and 4-day food records from a subsample of the cohort.¹⁸

Measures of Timing

For our primary analyses, we examined an interval from 4 weeks before to 8 weeks after the start of pregnancy. The

Figure 1. Derivation of the Study Sample

Approximately 283 000 children were invited to participate in the Norwegian Mother and Child Cohort Study; of these, approximately 174 000 declined to participate. ASD indicates autism spectrum disorder. *Numbers sum to more than 12 003 because some children met more than 1 exclusion criterion.

start of pregnancy was defined as the first day of the last menstrual period before conception, in keeping with the standard definition used in the follow-up of pregnant women in Norway. Children of mothers who used folic acid supplements during the entire or parts of the exposure interval were compared with children whose mothers did not use folic acid supplements during the interval. The exposure interval was chosen on the basis of an a priori hypothesis that the effect of folic acid on the development of the central nervous system is most prominent in this period, and it also corresponds to the interval used in the previous study of language delay.¹⁰ The interval covers or precedes events of critical importance to the fetal brain, such as the closure of the neural tube 28 days after conception (gestational week 6) and the embryonic period that includes development of the basic brain structures 15 to 56 days after conception (gestational weeks 5-10).¹⁹

Potential Confounders

We explored a number of factors that might influence a potential association between supplement use and ASD risk: parental education, parental age, whether the pregnancy was planned, maternal smoking during pregnancy, maternal body mass index (calculated as weight in kilograms divided by height in meters squared), weight gain at weeks 18 and 30, parity, and year of birth.

Statistical Analyses

Analyses were performed using SPSS version 19.0 (SPSS Inc). Odds ratios (ORs) with 95% CIs for the association between folic acid use and risk of each ASD were estimated from logistic regression models. The adjusted models included adjustment for year of birth, maternal education level, and parity, because these were the only covariates that had any influence on the OR estimates.

We estimated the power of these analyses for autistic disorder, which was the ASD subtype with the highest number of diagnosed cases in the study sample. The power calculations were based on the observed distributions of the outcome and the exposure, ie, an overall prevalence of 0.13% for autistic disorder and a proportion of 68% of the study sample exposed to folic acid within the exposure interval. The type I error probability was set at $\alpha = .05$ (2-sided). Under these conditions we had a power of 93% to detect an OR of 0.50, 73% to detect an OR of 0.60, 45% to detect an OR of 0.70, and 18% to detect an OR of 0.80.

To assess the possibility of residual confounding, we explored whether maternal illness and medication use during pregnancy had any effect on association. Information about maternal illness and medication use was obtained from the questionnaire completed in week 18 and from the Medical Birth Registry. We adjusted the logistic regression models for the presence of anxiety, depression, epilepsy, preeclampsia, and diabetes during pregnancy (separately for each disorder).

We also made separate adjustments for use of medications for anxiety, depression, and epilepsy and for the use of hormone treatment and in vitro fertilization to become pregnant.

We conducted a secondary analysis of the association between maternal use of fish oil supplements and the risk of ASD, to investigate whether the associations were specific to folic acid or similar across different types of supplements. If they were similar, the associations would more likely be attributable to health-conscious maternal behaviors in general and not the supplements per se.²⁰ We also examined the association between folic acid use in week 22 of pregnancy and subsequent risk of ASD, to evaluate whether any associations, if present, were similar in early pregnancy and mid pregnancy.

The study did not have sufficient power for subgroup analyses, but we performed some exploratory analyses for the autistic disorder subtype to look for clues to interactions that could be tested in future studies. We explored (1) the timing of initiation of folic acid supplementation; (2) maternal use of other vitamins, minerals, or both from 4 weeks before to 8 weeks after the start of pregnancy; (3) maternal total daily intake of folate in week 22 (diet and supplements combined, adjusted for dietary folate equivalents); (4) stratification of autistic disorder cases by language level at 36 months; and (5) stratification of the study sample by year of birth (2002-2004 vs 2005-2008).

RESULTS


The derivation of the study sample is shown in FIGURE 1. A total of 97 179 cohort participants were eligible for the analyses. To isolate folic acid exposure from other exposure reported to increase the risk of ASD, we excluded children with gestational age less than 32 weeks at birth, children with birth weight less than 2500 g, and multiple births. We also excluded children for whom we did not have data on maternal supplement use before conception and in early pregnancy as well as children whose mothers reported supple-

ment use but had not specified the type and duration. In total, 12 003 children were excluded, for 1 or more reasons. The final study sample included 85 176 children. At the end of follow-up, the age range was 3.3 through 10.2 years (mean, 6.4 years).

A total of 270 children (0.32%) in the study sample have been diagnosed with ASDs: 114 (0.13%) with autistic disorder, 56 (0.07%) with Asperger syndrome, and 100 (0.12%) with PDD-NOS. The distribution of ASD cases by year of birth is shown in eTable 1, available at <http://www.jama.com>. Of the ASD cases, 135 (50.0%) had been clinically assessed through the ABC study. The remaining 135 had specialist-confirmed diagnoses of ASD recorded in the Norwegian Patient Registry. Registry diagnoses had a high validity for ASD as a whole: of the 39 children assessed in the ABC study after being detected through the registry, 38 were found to meet DSM-IV criteria for ASD, generating a positive predictive value (PPV) of 97% (95% CI, 87%-100%). Estimates of PPV are lower for the individual ASD subtype diagnoses: 80% (12/15 [95% CI, 52%-96%]) for autistic disorder, 38% (5/13 [95% CI, 14%-68%]) for Asperger syndrome, and 73% (8/11 [95% CI, 39%-94%]) for PDD-NOS. Estimates of PPV for the subtype diagnoses are preliminary, because the number of cases in each group is still low.

The proportions of mothers reporting folic acid use are shown in FIGURE 2. In the first interval (weeks 4 to 1 before the start of pregnancy), 32.9% of mothers took folic acid. The proportion increased to 70.7% in weeks 9 through 12 and then reverted to 45.8% in weeks 13 through 16. The distribution of folic acid use across categories of parent and child characteristics is shown in TABLE 1. Women who used folic acid within the exposure interval (4 weeks before to 8 weeks after the start of pregnancy) were more likely to have college- or university-level education, to have planned the pregnancy, to be nonsmokers, to have prepregnancy body mass index below

Figure 2. Folic Acid Supplement Use by Pregnancy Interval



25, and to be first-time mothers. Folic acid use increased substantially by year of birth, from 43.2% in 2002 to 83.7% in 2008.

Women who took folic acid in early pregnancy had a higher response rate to the screening questionnaire completed when the children were aged 36 months. For the study sample overall, the response rate was 62% in folic acid users and 55% in nonusers. For children born in 2005-2008, ie, the youngest children, the difference was somewhat larger, with a response rate of 61% in folic acid users and 50% in nonusers. Consequently, children with ASDs born to women who used folic acid may have had a higher probability of being diagnosed at an early age.

Results of the logistic regression analysis for autistic disorder are reported in TABLE 2. There was an inverse association between folic acid use and subsequent risk of autistic disorder. Autistic disorder was present in 0.10% (64/61 042) of children whose mothers took folic acid, compared with 0.21% (50/24 134) in children whose mothers did not take folic acid. The ad-

justed OR of autistic disorder was 0.61 (95% CI, 0.41-0.90) in children of folic acid users. Adjustment for maternal illness and medication use did not affect the OR (eTable 2).

The use of fish oil supplements followed patterns similar to those for folic acid use in the study sample: it was associated with the same parental characteristics (eTable 3), it increased throughout the period of recruitment to the cohort (eTable 3), and it increased from before pregnancy through the first trimester (eFigure). Despite these similarities, there was no association between use of fish oil supplements and risk of autistic disorder, as shown in TABLE 3. The adjusted OR of autistic disorder was 1.29 (95% CI, 0.88-1.89) in children of mothers who used fish oil supplements.

The inverse association found for folic acid use in early pregnancy was absent for folic acid use in mid pregnancy: the adjusted OR for autistic disorder was 0.96 (95% CI, 0.60-1.55) for mothers taking 400 μ g or more per day in week 22 and 1.02 (95% CI, 0.62-1.67) for those taking less than 400 μ g per day at that time (Table 3).

Table 1. Parent and Child Characteristics by Maternal Folic Acid Use^a

Characteristic	No. (%)		
	Total Study Sample (N = 85 176)	Folic Acid Use, wk -4 to 8 ^b	
		No (n = 24 134)	Yes (n = 61 042)
Maternal education, y			
<12	6264 (7.4)	3274 (13.6)	2990 (4.9)
12	22 616 (26.6)	8319 (34.5)	14 297 (23.4)
13-16	34 641 (40.7)	8298 (34.4)	26 343 (43.2)
≥17	19 910 (23.4)	3611 (15.0)	16 299 (26.7)
Missing data	1745 (2.0)	632 (2.6)	1113 (1.8)
Paternal education, y			
<12	9067 (10.6)	3915 (16.2)	5152 (8.4)
12	32 161 (37.8)	10 434 (43.2)	21 727 (35.6)
13-16	22 476 (26.4)	5248 (21.7)	17 228 (28.2)
≥17	18 835 (22.1)	3541 (14.7)	15 294 (25.1)
Missing data	2637 (3.1)	996 (4.1)	1641 (2.7)
Maternal age, y			
<25	9384 (11.0)	3785 (15.7)	5599 (9.2)
25-29	28 107 (33.0)	7450 (30.9)	20 657 (33.8)
30-34	32 975 (38.7)	8551 (35.4)	24 424 (40.0)
≥35	14 710 (17.3)	4348 (18.0)	10 362 (17.0)
Paternal age, y			
<25	4041 (4.7)	1709 (7.1)	2332 (3.8)
25-29	19 167 (22.5)	5331 (22.1)	13 836 (22.7)
30-34	33 101 (38.9)	8629 (35.8)	24 472 (40.1)
35-39	20 231 (23.8)	5644 (23.4)	14 587 (23.9)
≥40	8411 (9.9)	2734 (11.3)	5677 (9.3)
Missing data	225 (0.3)	87 (0.4)	138 (0.2)
Planned pregnancy			
Yes	68 094 (79.9)	17 394 (72.1)	50 700 (83.1)
No	16 061 (18.9)	6351 (26.3)	9710 (15.9)
Missing data	1021 (1.2)	389 (1.6)	632 (1.0)
Maternal smoking ^c			
No	77 845 (91.4)	20 641 (85.5)	57 204 (93.7)
Yes	6740 (7.9)	3254 (13.5)	3486 (5.7)
Missing data	591 (0.7)	239 (1.0)	352 (0.6)
Maternal prepregnancy BMI ^d			
<25	56 614 (66.5)	15 150 (62.8)	41 464 (67.9)
25-29	18 332 (21.5)	5441 (22.5)	12 891 (21.1)
30-34	5830 (6.8)	1951 (8.1)	3879 (6.4)
≥35	2158 (2.5)	719 (3.0)	1439 (2.4)
Missing data	2242 (2.6)	873 (3.6)	1369 (2.2)
Parity ^e			
0	37 946 (44.6)	9266 (38.4)	28 680 (47.0)
1	30 674 (36.0)	8493 (35.2)	22 181 (36.3)
≥2	16 556 (19.4)	6375 (26.4)	10 181 (16.7)
Year of birth ^f			
2002	7377 (8.7)	4187 (56.8)	3190 (43.2)
2003	10 858 (12.7)	5030 (46.3)	5828 (53.7)
2004	11 882 (13.9)	3682 (31.0)	8200 (69.0)
2005	13 711 (16.1)	3504 (25.6)	10 207 (74.4)
2006	15 364 (18.0)	3246 (21.1)	12 118 (78.9)
2007	14 140 (16.6)	2552 (18.0)	11 588 (82.0)
2008	11 844 (13.9)	1933 (16.3)	9911 (83.7)

Abbreviation: BMI, body mass index.

^aP < .001 for all variables, 2-sided χ^2 test for independence.

^bInterval from 4 weeks before to 8 weeks after start of pregnancy.

^cMaternal smoking, daily or occasionally, during pregnancy.

^dCalculated as weight in kilograms divided by height in meters squared.

^eParity including previous miscarriage or abortion after week 22 of gestation.

^fPercentages in the total study sample column calculated using the total study sample as the denominator; percentages in the folic acid use columns were calculated using the row Ns as denominators.

For Asperger syndrome and PDD-NOS, we restricted the analyses to birth years with a cumulative incidence of 0.08% or higher (higher than the lowest level observed for autistic disorder): 2002-2004 for Asperger syndrome (n=30 117, including 48 cases) and 2002-2006 for PDD-NOS (n=59 152, including 91 cases). Our power to detect an OR of magnitude similar to that found for autistic disorder (OR, 0.61) was limited: 36% for Asperger syndrome and 61% for PDD-NOS. For Asperger syndrome, the proportion of diagnosed cases was 0.12% (21/17 218) in children of folic acid users and 0.21% (27/12 899) in children of nonusers, generating an adjusted OR of 0.65 (95% CI, 0.36-1.16). For PDD-NOS, the proportion was 0.15% (58/39 543) in children of folic acid users and 0.17% (33/19 649) in children of nonusers, generating an adjusted OR of 1.04 (95% CI, 0.66-1.63).

Results of exploratory analyses are reported in TABLE 4. These results should be cautiously interpreted, because none of the exploratory analyses had a statistical power of more than 50% to detect an OR of 0.60. There did not seem to be a strong gradient in risk by timing of initiation of folic acid use within the primary exposure interval. The use of other vitamins and minerals in addition to folic acid did not appear to affect risk of autistic disorder. The analyses based on the food frequency questionnaire data from week 22 did not reveal any apparent association between maternal total daily folate intake in week 22 (diet and supplements combined) and subsequent risk of autistic disorder in children. The analysis in which cases were stratified according to language level suggested that the inverse association may be strong in children with severe language delay and weak in those with moderate or no delay. The analysis stratified by year of birth suggested that the inverse association may be stronger in the older children (born in 2002-2004) than in the younger children (born in 2005-2008).

COMMENT

This study found that maternal use of supplemental folic acid from 4 weeks before to 8 weeks after the start of pregnancy was associated with a lower risk of autistic disorder—the most severe form of ASD—in children.

Use of folic acid supplements was associated with higher socioeconomic status and more health-conscious maternal behavior patterns in the study sample. We cannot exclude the possibility that some portion of the inverse association represents residual, unmeasured confounding. However, if residual confounding was substantial, we would have expected to find a lowering of risk associated with fish oil supplement use as well, because the use of fish oil was associated with the same parental characteristics in the study sample. No such lowering of risk was observed. We also would have expected the inverse association between folic acid use and autistic disorder risk to persist in mid pregnancy (week 22), which it did not. There was no evidence of residual confounding in analyses adjusting for maternal illness and medication, which might reflect the fact that the pregnant women in the cohort were generally healthy and had low proportions of medication use during pregnancy. We did not have data on more rare psychiatric disorders, but we believe that such disorders are unlikely to have had any significant influence.

Our findings indicate that the inverse association may be largely driven by the children with autistic disorder and severe language delay at 36 months, who were presumably the more severely affected children. It is also worth noting that the OR estimate for those with missing data on language level (nonresponders to the screening questionnaire) was similar to that for those with severe language delay. This suggests that mothers with severely affected children may have had lower response rates and that an ascertainment bias may have been present. The possibility of such bias, combined with the small numbers in each stratum, war-

rants caution in the interpretation of these findings.

The participation rate among women invited to participate in MoBa was 38.5%, and the cohort is not fully representative of the Norwegian population. Comparisons with nationwide registry data have demonstrated that the mothers in the cohort were more likely to be first-time mothers, less likely to be single mothers, and had higher levels of education, higher mean age, and lower levels of smoking than other pregnant women.²¹

We tested the generalizability of our findings by replicating the analyses in a nationwide data file containing data from the Medical Birth Registry of Norway, the Norwegian Patient Registry, and Statistics Norway. We included children born in 1999-2007 and applied the same inclusion criteria as for the MoBa-based analyses. The replication sample included 473 095 children, of whom 822 (0.17%) had diagnoses of autistic disorder recorded by Norwegian specialist health services. Folic acid use is substantially under-

reported in the Medical Birth Registry; our comparisons with the MoBa questionnaire data found that half of the mothers reported in the registry to be nonusers of folic acid actually had reported folic acid use in the questionnaires. This underreporting is a major limitation and will bias association measures toward the null. Despite this, we did find a significant inverse association in the nationwide sample: mothers with reported folic acid use had an adjusted OR of 0.83 (95% CI, 0.71-0.97) for autistic disorder in their children. When the MoBa participants were analyzed using the registry-based folic acid variable, the adjusted OR was 0.75 (95% CI, 0.46-0.96). The similarity between MoBa participants and nonparticipants suggest that our MoBa-based analyses have not been significantly affected by selection bias.

The strengths of the study were the cohort design, large sample size, and prospective data collection as well as the combination of screening, referrals, and registry linkage for detection of ASD cases. The richness of the exposure data

Table 2. Risk of Autistic Disorder According to Maternal Folic Acid Use

Folic Acid Use	No. (%)		OR (95% CI)	
	Total	Autistic Disorder	Unadjusted	Adjusted ^a
No	24 134 (28.3)	50 (0.21)	1 [Reference]	1 [Reference]
Yes	61 042 (71.7)	64 (0.10)	0.51 (0.35-0.73)	0.61 (0.41-0.90)

Abbreviation: OR, odds ratio.

^aAdjusted for year of birth, maternal education level, and parity. For maternal education, missing data were included as a separate category in the logistic regression model.

Table 3. Risk of Autistic Disorder According to Fish Oil Use in Weeks –4 to 8 and Folic Acid Use in Week 22

Supplement Use	No. (%)		OR (95% CI)	
	Total	Autistic Disorder	Unadjusted	Adjusted ^a
Fish oil use in wk –4 to 8 ^b				
None	46 314 (54.4)	60 (0.13)	1 [Reference]	1 [Reference]
Any	38 862 (45.6)	54 (0.14)	1.07 (0.74-1.55)	1.29 (0.88-1.89)
Folic acid use in wk 22, µg/d ^c				
None	32 064 (40.4)	42 (0.13)	1 [Reference]	1 [Reference]
1-399	20 872 (26.3)	26 (0.12)	0.95 (0.58-1.55)	1.02 (0.62-1.67)
≥400	26 467 (33.3)	31 (0.12)	0.89 (0.56-1.42)	0.96 (0.60-1.55)

Abbreviations: OR, odds ratio.

^aAdjusted for year of birth, maternal education level, and parity. For maternal education, missing data were included as a separate category in the logistic regression model.

^bFish oil includes cod liver oil and omega-3 fatty acid supplements. Interval denotes 4 weeks before to 8 weeks after start of pregnancy.

^cAnalyses includes only responders to the food frequency questionnaire in week 22 (n=79 403). The food frequency questionnaire included report of brand names of supplements, enabling exact calculations of the amounts of folic acid ingested per day.

allowed for differentiations between different supplements and between the various stages of pregnancy. Our ability to compare the study sample with a nationwide sample was also an advantage.

The main limitation was the incomplete ascertainment of ASD cases in the cohort. The prevalence of diagnosed ASD was lower than what has been reported in the United Kingdom and the United States,^{22,23} although that discrepancy is not merely attributable to underascertainment,

because the nationwide ASD prevalence is also lower in Norway.²⁴ For the country as a whole, the prevalence is estimated to be 0.8% in 12-year-olds,²⁴ which is not very different from the 0.66% prevalence observed for children born in 2002 and 2003 in the MoBa cohort (eTable 1). Underascertainment was less of a problem for autistic disorder than for the other ASD subtypes, but it was still reassuring that the inverse association for autistic disorder was stron-

ger in the older children (born in 2002-2004), for whom case ascertainment was closer to completion. The relative weakness of the inverse association among the younger children (born in 2005-2008) may have resulted from the fact that mothers who took prenatal folic acid supplements had higher questionnaire response rates, causing the ASD cases among their children to be identified earlier. As mentioned previously, there also was the possibility of ascertainment bias

Table 4. Exploratory Analyses

Analysis	No. (%)		OR (95% CI)	
	Total	Autistic Disorder	Unadjusted	Adjusted ^a
Initiation of folic acid				
No folic acid	14 721 (17.3)	32 (0.22)	1 [Reference]	1 [Reference]
Initiation wk				
-4 to -1	28 061 (32.9)	32 (0.11)	0.52 (0.32-0.86)	0.67 (0.40-1.14)
1 to 4	16 797 (19.7)	18 (0.11)	0.49 (0.28-0.88)	0.58 (0.32-1.05)
5 to 8	16 184 (19.0)	14 (0.09)	0.40 (0.21-0.75)	0.44 (0.23-0.83)
9 to 16	9395 (11.0)	18 (0.19)	0.88 (0.49-1.57)	0.87 (0.49-1.57)
Use of other vitamins and minerals in wk -4 to 8^b				
No vitamins or minerals	21 106 (24.8)	44 (0.21)	1 [Reference]	1 [Reference]
Other vitamins or minerals, no folic acid	3028 (3.6)	6 (0.20)	0.95 (0.41-2.23)	0.93 (0.40-2.19)
Folic acid only	29 075 (34.1)	31 (0.11)	0.51 (0.32-0.81)	0.62 (0.38-1.00)
Folic acid plus other vitamins or minerals	31 967 (37.5)	33 (0.10)	0.50 (0.32-0.78)	0.58 (0.36-0.94)
Total daily folate intake in wk 22^c				
Quartile, (mean [range]), μg				
1 (209 [62-272])	19 611 (24.7)	26 (0.13)	1 [Reference]	1 [Reference]
2 (345 [272-434])	19 634 (24.7)	22 (0.11)	0.85 (0.48-1.49)	0.88 (0.50-1.55)
3 (560 [434-667])	19 485 (24.5)	26 (0.13)	1.01 (0.58-1.73)	1.08 (0.62-1.87)
4 (874 [667-5673])	19 429 (24.5)	23 (0.12)	0.89 (0.51-1.57)	0.97 (0.55-1.72)
Intake not quantified ^d	1244 (1.6)	2 (0.16)	1.21 (0.29-5.12)	1.01 (0.24-4.27)
Autistic disorder cases stratified by language level at 36 mo^e				
Severe language delay				
No folic acid	24 134 (28.3)	18 (0.07)	1 [Reference]	1 [Reference]
Use of folic acid	61 042 (71.7)	18 (0.03)	0.40 (0.21-0.76)	0.49 (0.25-0.99)
Moderate or no language delay				
No folic acid	24 134 (28.3)	13 (0.05)	1 [Reference]	1 [Reference]
Use of folic acid	61 042 (71.7)	29 (0.05)	0.88 (0.46-1.70)	0.91 (0.46-1.81)
Missing data				
No folic acid	24 134 (28.3)	19 (0.08)	1 [Reference]	1 [Reference]
Use of folic acid	61 042 (71.7)	17 (0.03)	0.35 (0.18-0.68)	0.48 (0.24-0.96)
Study sample stratified by year of birth				
2002-04				
No folic acid	12 899 (42.8)	37 (0.29)	1 [Reference]	1 [Reference]
Use of folic acid	17 218 (57.2)	21 (0.12)	0.42 (0.25-0.73)	0.45 (0.26-0.79)
2005-08				
No folic acid	11 235 (20.4)	13 (0.12)	1 [Reference]	1 [Reference]
Use of folic acid	43 824 (79.6)	43 (0.10)	0.85 (0.46-1.58)	0.84 (0.45-1.59)

Abbreviation: OR, odds ratio.

^aAdjusted for year of birth, maternal education level, and parity. For maternal education, missing data were included as a separate category in the logistic regression models. The analysis stratified by year of birth was adjusted for maternal education level and parity.

^bInterval from 4 weeks before to 8 weeks after start of pregnancy.

^cAnalyses include only responders to the food frequency questionnaire in week 22 (n=79 403). The questionnaire included report of brand names of supplements, enabling exact calculations of the amounts of folic acid ingested per day. Dietary intake was adjusted for dietary folate equivalents when total intake was calculated.

^dNot quantified because reported daily energy intake was outside the valid range, ie, less than 4500 kJ/d or greater than 20 000 kJ/d.

^eInformation on language skills was obtained from the Mother and Child Cohort Study 36-month questionnaire, and data were missing for children whose mothers had not responded to that questionnaire.

arising from lower response rates among parents of the children more severely affected with autistic disorder. If such bias were present, the OR estimate for the younger children would be biased toward the null.

Another limitation of the study was the reliance on subtype diagnoses of ASD. These have not been found to have high reliability across assessment sites in studies in the United States and may be removed altogether from the upcoming DSM-V classification system.²⁵ Our own validation of registry diagnoses indicated that subtype diagnoses were less reliable than for ASD as a whole, but there was still a high level of agreement (PPV, 80%) for autistic disorder diagnoses, which was the outcome of primary interest.

Our main finding was that maternal use of folic acid supplements around the time of conception was associated with a lower risk of autistic disorder. This finding does not establish a causal relation between folic acid use and au-

tistic disorder but provides a rationale for replicating the analyses in other study samples and further investigating genetic factors and other biological mechanisms that may explain the inverse association.

Author Contributions: Drs Susser and Stoltenberg had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Susser and Stoltenberg served as joint senior authors.

Study concept and design: Surén, Roth, Hirtz, Davey Smith, Susser, Stoltenberg.

Acquisition of data: Surén, Roth, Haugen, Hornig, Lie, Magnus, Reichborn-Kjennerud, Schjølberg, Øyen, Susser, Stoltenberg.

Analysis and interpretation of data: Surén, Roth, Bresnahan, Haugen, Hornig, Hirtz, Lipkin, Reichborn-Kjennerud, Susser, Stoltenberg.

Drafting of the manuscript: Surén, Roth, Bresnahan, Hornig, Hirtz, Davey Smith, Susser, Stoltenberg.

Critical revision of the manuscript for important intellectual content: Surén, Roth, Haugen, Hornig, Hirtz, Lie, Lipkin, Magnus, Reichborn-Kjennerud, Schjølberg, Øyen, Susser, Stoltenberg.

Statistical analysis: Surén, Roth, Hornig, Susser.

Obtained funding: Surén, Roth, Bresnahan, Hornig, Lie, Reichborn-Kjennerud, Schjølberg, Øyen, Susser, Stoltenberg.

Administrative, technical, or material support: Roth, Lie, Lipkin, Øyen, Susser, Stoltenberg.

Study supervision: Hirtz, Lipkin, Magnus, Reichborn-Kjennerud, Davey Smith, Stoltenberg.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Haugen reported receiving payment for lectures at the University of Oslo and Agder. No other authors reported disclosures.

Funding/Support: The Norwegian Mother and Child Cohort is supported by the Norwegian Ministry of Health and Care Services, the Norwegian Ministry of Education and Research, the Research Council of Norway/FUGE (grant 151918), the National Institute of Neurological Disorders and Stroke (NINDS) (grant NS47537 [Dr Lipkin]), and the National Institute of Environmental Health Sciences (NIEHS) (contract NO-ES-75558). The Autism Birth Cohort study is funded by the NINDS (grant NS47537 [Dr Lipkin]). Dr Surén's salary is funded by the Research Council of Norway (grants 185476 and 190694).

Role of the Sponsors: Dr Hirtz, the Scientific Program Officer for the Autism Birth Cohort study at NINDS, participated in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; and the preparation of the manuscript. The Norwegian Ministry of Health and Care Services, the Norwegian Ministry of Education and Research, the Research Council of Norway/FUGE, and the NIEHS had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, and approval of the manuscript.

Online-Only Material: eTables 1-3, eFigure, and Author Video Interview are available at <http://www.jama.com>.

Additional Contributions: We are grateful to all the families in Norway who take part in these ongoing studies.

REFERENCES

- Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N Engl J Med*. 1992;327(26):1832-1835.
- Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. *JAMA*. 1993;269(10):1257-1261.
- Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects: implications for prevention. *JAMA*. 1995;274(21):1698-1702.
- Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. *Epidemiology*. 1995;6(3):219-226.
- Berry RJ, Li Z, Erickson JD, et al; China-U.S. Collaborative Project for Neural Tube Defect Prevention. Prevention of neural-tube defects with folic acid in China. *N Engl J Med*. 1999;341(20):1485-1490.
- Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. *JAMA*. 1989;262(20):2847-2852.
- MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet*. 1991;338(8760):131-137.
- Centers for Disease Control and Prevention (CDC). CDC Grand Rounds: additional opportunities to prevent neural tube defects with folic acid fortification. *MMWR Morb Mortal Wkly Rep*. 2010;59(31):980-984.
- Scientific Advisory Committee on Nutrition. Folate and Disease Prevention. Scientific Advisory Committee on Nutrition website. http://www.sacn.gov.uk/pdfs/folate_and_disease_prevention_report.pdf. 2006. Accessed December 21, 2012.
- Roth C, Magnus P, Schjølberg S, et al. Folic acid supplements in pregnancy and severe language delay in children. *JAMA*. 2011;306(14):1566-1573.
- Schmidt RJ, Hansen RL, Hartiala J, et al. Prenatal vitamins, one-carbon metabolism gene variants, and risk for autism. *Epidemiology*. 2011;22(4):476-485.
- Schmidt RJ, Tancredi DJ, Ozonoff S, et al. Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. *Am J Clin Nutr*. 2012;96(1):80-89.
- Magnus P, Irgens LM, Haug K, Nystad W, Skjaerven R, Stoltenberg C; MoBa Study Group. Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). *Int J Epidemiol*. 2006;35(5):1146-1150.
- Stoltenberg C, Schjølberg S, Bresnahan M, et al; ABC Study Group. The Autism Birth Cohort: a paradigm for gene-environment-timing research. *Mol Psychiatry*. 2010;15(7):676-680.
- Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *J Autism Dev Disord*. 1994;24(5):659-685.
- Lord C, Risi S, Lambrecht L, et al. The Autism Diagnostic Observation Schedule-Generic: a standard measure of social and communication deficits associated with the spectrum of autism. *J Autism Dev Disord*. 2000;30(3):205-223.
- Meltzer HM, Brantsaeter AL, Ydersbond TA, Alexander J, Haugen M. Methodological challenges when monitoring the diet of pregnant women in a large study: experiences from the Norwegian Mother and Child Cohort Study (MoBa). *Matern Child Nutr*. 2008;4(1):14-27.
- Brantsaeter AL, Haugen M, Alexander J, Meltzer HM. Validity of a new food frequency questionnaire for pregnant women in the Norwegian Mother and Child Cohort Study (MoBa). *Matern Child Nutr*. 2008;4(1):28-43.
- Sadler TW. *Langman's Medical Embryology*. Baltimore, MD: Lippincott Williams & Wilkins; 2010.
- Smith GD. Assessing intrauterine influences on offspring health outcomes: can epidemiological studies yield robust findings? *Basic Clin Pharmacol Toxicol*. 2008;102(2):245-256.
- Nilsen RM, Vollset SE, Gjessing HK, et al. Self-selection and bias in a large prospective pregnancy cohort in Norway. *Paediatr Perinat Epidemiol*. 2009;23(6):597-608.
- Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). *Lancet*. 2006;368(9531):210-215.
- Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders—Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. *MMWR Surveill Summ*. 2012;61(3):1-19.
- Surén P, Bakken IJ, Aase H, et al. Autism spectrum disorder, ADHD, epilepsy, and cerebral palsy in Norwegian children. *Pediatrics*. 2012;130(1):e152-e158.
- Lord C, Petkova E, Hus V, et al. A multisite study of the clinical diagnosis of different autism spectrum disorders. *Arch Gen Psychiatry*. 2012;69(3):306-313.